sur Xenetic Biosciences, Inc. (NASDAQ:XBIO)
Xenetic Biosciences' Abstract Accepted for SITC 2025 Meeting
Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting. This event will take place from March 12 to 14, 2025, in San Diego, CA, and also virtually.
The abstract, titled "DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma," will be presented by Dr. Alexey Stepanov from The Scripps Research Institute. The presentation is scheduled for March 12, 2025, from 5:10 p.m. to 6:45 p.m. PT.
Xenetic Biosciences focuses on developing immuno-oncology technologies for hard-to-treat cancers. The DNase platform aims to enhance treatment outcomes by targeting neutrophil extracellular traps in various cancers.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Xenetic Biosciences, Inc.